Quellenangaben: HIV-/AIDS-Forschung - Tierversuche haben versagt

1. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-1893.

2. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372(9653):1894-1905.

3. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008;372(9653):1857-1858.

4. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3(12):1389-1393.

5. Diseases NI. Clinical Trials of HIV Vaccines: National Institutes of Health. U.S. Department of Health and Human Services, 2007.

6. Gardner M, Luciw P. Animal Models of AIDS. FASEB Journal 1989;3:2593-2606.

7. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985;82(20):7096-7100.

8. Soudeyns H, Yao XI, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35(7):1386-1390.

9. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248(4953):358-361.